The GW VRU Director, Dr. David Diemert, weighs in on two candidate vaccine viruses for H5N1 bird flu that could be used to make vaccines.
Bird Flu: U.S. Could Produce and Ship 100 Million Vaccine Doses Within Months
Latest News
Latest news about the results of the COVAIL trial regarding the Sanofi booster. GW participated as one of the many sites for this COVID-19 vaccine study.
The GW VRU contributed critical data needed to approve the use of the Mpox vaccine in adolescents. This is of huge importance given the current Mpox outbreak has yet to be controlled and has disproportionately impacted children in this wave.
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.